Top Markets
Coin of the day
Inventiva S.A. Inventiva S.A.

Inventiva S.A.

IVA
Rank in Stocks #8990
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Share Price
$4.74
Last synced: 2026-08-28
Market Cap
$1.12B
Change (1 day)
-5.77%
Change (1 year)
-16.96%
Country
FR
Trade Inventiva S.A. (IVA)

Category

Stock price history for Inventiva S.A. (IVA)
Highest end of day price: $4.81 on 2026-08-01

Lowest end of day price: $8.81 on 2017-02-01
Stock price history of Inventiva S.A. from 2017 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) 16.21%
2025 81.56%
2024 -45.71%
2023 -2.51%
2022 -66.57%
2021 5.74%
2020 247.99%
2019 -44.55%
2018 -2.05%
2017 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.53 -12.70%
AU
$138.18 473.58%
US
$759.27 7.20%
CH